• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    ProMIS Released Its Financial Results for Q2 2017

    Bryan Mc Govern
    Aug. 11, 2017 09:05AM PST
    Biotech Investing

    ProMIS Neurosciences shared its financial and operational results for the second quarter of 2017.

    ProMIS Neurosciences (TSX:PMN) shared its financial and operational results for the second quarter of 2017.
    As quoted in the press release:

    Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO, stated, “We are pleased with the substantial progress achieved at ProMIS. Our main focus now is to advance the development of our lead product candidates for Alzheimer’s disease, PMN310 and PMN350, with particular emphasis on the preclinical program to differentiate our leads compared to competitive antibody products in development. We remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta may lead to best in class therapies and significant long-term value creation.”
    Financial Results
    Results of Operations – Three months ended June 30, 2017 and 2016
    The net loss for the three months ended June 30, 2017 was $1,903,396, compared to a net loss of $711,942 for the three months ended June 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.

    Click here to read the full press release.

    Source: www.newswire.ca

    promis neurosciencesproduct candidatesfinancial results
    The Conversation (0)

    Go Deeper

    AI Powered

    ProMIS Neurosciences' Research Agreement with University Gets Grant

    Pharmaceutical Investing

    ProMetic Obtains FDA Clearance for Phase 2/3 Trials

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×